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Abstract: Nasal polyps are common, affecting up to four percent of the population. Their 
etiology remains unclear, but they are known to have associations with allergy, asthma, infection, 
cystic ﬁ  brosis, and aspirin sensitivity. They present with nasal obstruction, anosmia, rhinorrhoea, 
post nasal drip, and less commonly facial pain. Clinical examination reveals single or multiple 
grey polypoid masses in the nasal cavity. Computerized tomography allows evaluation of the 
extent of the disease and is essential if surgical treatment is to be considered. Management of 
polyposis involves a combination of medical therapy and surgery. There is good evidence for 
the use of corticosteroids (systemic and topical) both as primary treatment and as postoperative 
prophylaxis against recurrence. Surgical treatment has been reﬁ  ned signiﬁ  cantly over the past 
twenty years with the advent of endoscopic sinus surgery and, in general, is reserved for cases 
refractory to medical treatment. Recurrence of the polyposis is common with severe disease 
recurring in up to ten percent of patients.
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Introduction
Nasal polyps (NP) are benign lesions arising from the mucosa of the nasal sinuses 
(commonly at the outﬂ  ow tract of one or more of the sinuses) or from the mucosa of 
the nasal cavity. Having an uncertain etiology and a tendency to recur, they represent 
a challenging diagnosis for the physician to treat. Management of NP forms a large 
part of the workload for the otolaryngologist, especially for those with an interest in 
rhinology.
In addition, it is important for the respiratory physician to be aware of aspects 
of the treatment of NP which can have a signiﬁ  cant impact on chronic obstructive 
pulmonary disease, in particular asthma.
This paper aims to summarize current trends in all aspects of management of NP.
Search strategy and sources
We searched MEDLINE® for papers (1977–2007) using “nasal polyposis”, “polyps”, 
“diagnosis”, and “management” as keywords. We also searched the Cochrane database 
of systematic reviews using the keywords “nasal polyposis” and “polyps”. In addition, 
we used a personal archive of references relating to our clinical experience.
Etiology of nasal polyposis
The etiology of NP is unknown. Some theories consider polyps a consequence of con-
ditions which cause chronic inﬂ  ammation in the nose and nasal sinuses characterized 
by stromal edema and variable cellular inﬁ  ltrate (Bateman et al 2003). While many 
aspects have been documented to support this theory, the initiating cause remains 
unknown and may be different in many cases.
Historically it has been assumed that allergy predisposed to NP because the symp-
toms of watery rhinorrhea and mucosal swelling were present in both diseases along 
with an abundance of eosinophils in the nasal secretions. However, epidemiological Therapeutics and Clinical Risk Management 2008:4(2) 508
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studies provide little evidence to support this relationship 
with NP found in only 1%–2% of patients with positive skin 
prick tests (Settipane et al 1977). In addition, studies have 
shown that NP are no more common in atopic individuals 
(Jamal et al 1987). Studies have however shown that total 
and speciﬁ  c IgE as well as other allergic-type histologic 
features of polyps are unrelated to positive skin prick tests 
but did correlate with the levels of eosinophils (Bachert et al 
2001). It therefore remains possible that the local allergic 
mechanisms in the absence of systemic features could play 
a role in the pathogenesis of polyps.
Many studies have focussed on eosinophilic mediators in 
NP tissue and demonstrated that different cell types generate 
these mediators. Interleukine-5 (IL-5) has found to be signiﬁ  -
cantly raised in NP compared with healthy controls and the 
concentration of IL-5 was independent of the atopic status of 
the patient (Bachert et al 2001). The key role of IL-5 was sup-
ported by the ﬁ  nding that treatment of eosinophil-inﬁ  ltrated 
polyp tissue with neutralizing anti-IL-5 monoclonal antibody 
resulted in eosinophil apoptosis (Simon et al 1997). The 
regulation of the IL-5 receptor has also been investigated 
with down regulation being found to occur in NP, especially 
in association with asthma (Gaevert et al 2003).
An association between polyposis and fungal cultures 
has been established for many years (Saﬁ  rstein et al 1976). 
Further reports linked this ﬁ  nding with allergic bronchopul-
monary aspergillosis (Millar et al 1981). This recognition led 
to the term ‘allergic fungal sinusitis’ which is diagnosed by 
the presence of a positive RAS test to fungus, NP, comput-
erized tomography (CT) ﬁ  ndings of hyperdense material in 
the sinus cavity, allergic mucus with histological evidence 
of eosinophilic preponderance, and identiﬁ  cation of fungus 
in sinus mucus (Bent et al 1994; Ponikau et al 1999). This 
comes about because of a type 3 hypersensitivity reaction 
leading to repeated mucosal edema, antigen representation 
and resultant NP (Marple et al 2001). The precise nature of 
fungi in the pathogenesis of NP remains unsolved but further 
research will help clarify this in the future.
There is some evidence for a genetic element to NP. A 
link has been demonstrated recently between HLA-A74 and 
NP (Luxenburger et al 2000), but the current knowledge in 
this area remains very limited.
Medical conditions commonly associated with polyps 
include asthma, bronchiectasis, and cystic ﬁ  brosis (Settipane 
et al 1996). There is a well recognized subgroup of patients 
with Samnter’s Triad comprising polyposis, asthma, and 
aspirin hypersensitivity which makes up almost 10% of 
cases of NP.
Prevalence
In the general population, the prevalence of NP is considered 
to be around 4% (Hedman et al 1999). In cadaveric studies, 
this prevalence has been shown to be as high as 40% (Laren 
et al 1994).They predominantly affect adults and usually 
present in patients older than 20. They are uncommon in 
children under 10 and may be the presenting feature of cystic 
ﬁ  brosis. There is at least a 2:1 male to female preponderance. 
Up to a third of NP patients have asthma, whereas polyps are 
only found in 7% of asthmatics (Settipane et al 1996).
Clinical features
The main presenting symptom of NP is nasal obstruction 
which is constant but can vary depending on the site and 
size of the polyps. Sufferers will also frequently complain of 
watery rhinorrhea and postnasal drip. Anosmia or hyposmia 
with an ensuing alteration in taste are also characteristic 
symptoms of NP (Drake-Lee et al 1997).
Anterior and posterior rhinoscopy reveals single or 
multiple pale, grey polypoid masses arising most frequently 
from the middle meatus and prolapsing into the nasal cavity 
(Figure 1). They consist of loose connective tissue, edema, 
inﬂ  ammatory cells, and some capillaries and glands. They are 
covered with different types of epithelium, most commonly 
pseudostratiﬁ  ed respiratory epithelium with goblet cells 
and ciliated cells. Studies have shown that eosinophils are 
the most common inﬂ  ammatory cells in NP. This leads to a 
large proportion of IL-5 due to prolonged eosinophil survival 
and this is one of the important features in differentiating NP 
from rhinosinusitis at a histo-chemical level (Bachert et al 
1997). NP are almost invariably bilateral and when unilateral 
Figure 1 Typical appearance of nasal polyposis in right middle meatus. Therapeutics and Clinical Risk Management 2008:4(2) 509
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require histological examination to exclude malignancy or 
other pathology such as inverted papilloma (Drake-Lee et al 
2004). They are insensitive to palpation and rarely bleed.
The histological appearance of NP is characterized by 
ciliated columnar epithelium, thickening of the basement 
membrane, a loose avascular edematous stroma and an inﬁ  l-
trate of plasma cells and eosinophils. Eosinophils are found 
in 85% of NP with the remaining cells being predominantly 
neutrophils (Bachert et al 2003).
Investigations
Plain X-rays are insensitive and of no value in the diagno-
sis of NP but they may show opaciﬁ  cation of the affected 
sinuses (Iinuma et al 1994). A CT scan will show the extent 
of NP and anatomical variations and is essential if surgical 
treatment is to be implemented (Figure 2). It should not be 
regarded as the primary step in the diagnosis of the condi-
tion, except where there are unilateral signs and symptoms 
or other sinister features, but rather corroborates history and 
endoscopic ﬁ  ndings after failure of medical therapy.
A range of staging systems for CT scanning have been 
described, the most commonly used being the Lund-Mackay 
system (Lund et al 1993). This system relies on a score of 
0–2 dependent on the absence, partial, or complete opaci-
ﬁ  cation of each sinus system and of the vital ostiomeatal 
complex deriving a maximum score of 12 per side. This 
has been validated but the correlation between the CT score 
and symptoms has been shown to be poor and is not a good 
indicator of outcome (Browne et al 2006).
In unilateral cases of NP, an magnetic resonance imaging 
scan may aid diagnosis, particularly for investigations of 
more serious conditions such as neoplasia.
Treatment of NP
Therapy for NP involves a combination of observation, 
medical, and surgical treatments depending on individual 
case assessment. In general, patients are treated medically 
in the primary care setting before consideration of surgical 
procedures by an otolaryngologist. The aims of treatment 
are to eliminate or signiﬁ  cantly reduce the size of the NP 
resulting in relief of nasal obstruction, improvement in sinus 
drainage, restoration of olfaction and taste. Treatment of 
any accompanying rhinitic symptoms may also be required 
(Mygind et al 1999). With both treatments, recurrences are 
common, particularly in patients with asthma who are twice 
as likely to develop recurrence compared with nonasthmatics 
(Dinis et al 1997).
Medical treatment
The advent of topically administered corticosteroids has 
improved the treatment of upper (NP and rhinitis) and lower 
(asthma, chronic obstructive airways disease) airways disease 
(Fokkens et al 2007). Their clinical efﬁ  cacy is achieved by 
a combination of anti inﬂ  ammatory effects along with their 
ability to reduce airway eosinophillic inﬁ  ltration by pre-
venting their increased viability and activation (Burgel et al 
2004). Both topical and systemic glucocorticoids may affect 
the eosinophil function by both directly reducing eosinophil 
viability and function or indirectly reducing the secretion of 
chemotactic cytokines by nasal mucosa and polyp epithelial 
cells (Roca-Ferrer et al 1997). Corticosteroids form the 
mainstay of conservative therapy in NP as both a primary 
treatment and to prevent recurrence. In the absence of other 
warning signs such as pain, bleeding, or unilateral polyps, 
treatment can be largely conducted in the primary care set-
ting. Corticosteroids should be used with caution in ‘at-risk 
groups’ particularly patients with diabetes, uncontrolled 
hypertension, and peptic ulcer disease.
Treatment should commence with topical nasal steroids 
(Badia et al 2001) along with aggressive treatment of any 
underlying cause or comorbid allergy. Topical nasal steroids 
are delivered by drops or sprays. Nasal drops deliver a higher 
dose of medication to the middle meatus and the lying, 
head-back position has been shown to be both comfortable 
and effective (Kayarker et al 2002).Topical steroids have 
been investigated extensively. Stjarne and colleagues (2006) 
compared in 298 subjects with moderate NP mometasone  Figure 2 Coronal CT showing pan-opaciﬁ  cation of the sinuses.Therapeutics and Clinical Risk Management 2008:4(2) 510
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furoate nasal spray (MFNS) with placebo for 16 weeks. They 
found a signiﬁ  cant decrease in nasal congestion, polyp size, 
and improved quality of life. Lund and colleagues (1998) 
compared ﬂ  uticasone propionate (FP) with placebo in 46 
patients for 12 weeks in a randomized controlled trial. Polyp 
score and acoustic rhinometry improved signiﬁ  cantly in 
the NP group. Steroids have been shown to improve nasal 
breathing, improve symptoms of rhinitis, and reduce the size 
of NP along with the rate of recurrence (Patiar et al 2007). 
Despite this proven symptomatic beneﬁ  t, there remains 
debate however about the efﬁ  cacy of steroids in reduction 
of the proportion of patients requiring surgery (Browning 
et al 2007). One trial has certainly showed a reduced rate of 
surgical treatment, but it is acknowledged further research 
is required in this area (Albertien et al 2005).
Systemic steroids are reserved for advanced or refrac-
tory cases particularly when allergy is present. This form of 
treatment is used for relatively rapid short-term improvement 
due to the risk of adverse effects (Mygind et al 1996). This 
treatment is very effective. Van Camp and colleagues (1993) 
performed an open study giving 60 mg of prednisolone to 25 
patients with severe polyposis for four days then for each of 
the following twelve days reduced the dose by 5 mg daily; 
symptoms were improved especially obstruction and anosmia 
and CT ﬁ  ndings resolved in 52% of cases.
Hissaria and colleagues (2006) compared 50 mg predniso-
lone daily for 14 days with placebo. A signiﬁ  cant difference 
was found in nasal symptoms and endoscopic ﬁ  ndings. This 
sometimes dramatic improvement in anatomical appearance 
and symptom relief has been termed a ‘medical polypec-
tomy’. There is a paucity of evidence comparing systemic 
steroids with topical treatments. There are no randomized 
controlled trials in the literature comparing outcomes of sys-
temic steroids and surgery (Bateman et al 2003). The adverse 
effects of short-term steroid use include glucose intolerance, 
hypertension, adrenal suppression, gastro-intestinal bleeding, 
and altered mental state. Once symptoms have resolved, it is 
important to maintain improvement with long-term intranasal 
steroids in the form of aqueous nasal spray.
In all patients the addition of simple saline nasal douch-
ing to help cleanse the nose prior to topical medications is 
beneﬁ  cial (Fokkens et al 2007). These irrigations have been 
shown to improve nasal mucocilliary clearance measured 
by the saccharine test in both NP and healthy volunteers in 
an American study (Talbot et al 1997). These are typically 
available over the counter in most pharmacies.
Antibiotics are frequently used in chronic rhinsinusitis 
(Fokkens et al 2007) as well as in acute sinusitis but they are 
not effective in medical management of uncomplicated NP 
(Bateman et al 2003; Fokkens et al 2007). Mucolytics can 
be used as adjuncts to antibiotics in acute sinusitis to reduce 
viscosity of sinus secretion but no clinical trials have tested 
their effects in NP. Antihistamines can have signiﬁ  cant 
reduction in symptoms in simple NP. One study showed 
reduction in sneezing, rhinorrhea, and obstruction compared 
with placebo, but there was no reduction in polyp size at 
3 months (Haye et al 1998).
Other medical therapies have been used for treatment 
of NP. Leukotriene receptor antagonists have recently been 
shown to be effective (Kieff et al 2005), but larger scale tri-
als are required to prove their efﬁ  cacy. Topical capsaicin has 
also been shown to be effective, but side-effects including 
burning of the nasal mucosa limit its acceptability to patients 
(Baudoin et al 2000). There is little evidence to advocate the 
usage of other treatments including frusemide and interferon-
alpha2a and neither of these is available in routine medical 
practice (Bateman et al 2003).
Allergic fungal rhinosinusitis is treated by both topical 
and systemic antimycotics as an adjunct to sinus surgery. 
Surgery is considered the ﬁ  rst-line therapy particularly for 
invasive fungal rhinosinusitis (Schubert et al 2000). This 
management is however based on a small series of patients 
and case reports and should be considered as level 4 evi-
dence.
Surgical treatment
Surgical therapy is reserved for cases refractory to medical 
treatment. No single surgical technique has proved to be 
entirely curative and patients often undergo repeat procedures 
despite also receiving long-term medical therapy. Recurrence 
is common with severe disease recurring in around 5%–10% 
patients (Fokkens et al 2007).
Surgical techniques have been signiﬁ  cantly reﬁ  ned over 
the past 20 years with the advent of endoscopic sinus surgery 
(ESS) (Kennedy et al 2001). With a better understanding 
of the anatomy of the osteomeatal complex (Figure 3) and 
pathways of mucocilliary clearance, ESS is now the main-
stay of treatment for NP. In the National Health Service 
Research and Development Health Technology Assessment 
Programme Evaluation, polyp recurrence was 28% follow-
ing endoscopic sinus surgery compared with 35% following 
intranasal polypectomy (Dalziel et al 2003).
Hopkins and colleagues analyzed 1848 patients with 
nasal polyps who participated in the National Compara-
tive Audit of Surgery for Nasal polyposis and Rhinosi-
nusitis. The postoperative symptom scores did not differ Therapeutics and Clinical Risk Management 2008:4(2) 511
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signiﬁ  cantly after 12 and 36 months but revision surgery 
was carried out more frequently in the polypectomy only 
group in the ﬁ  rst twelve months after surgery (Hopkins 
et al 2006).
Despite this, many surgeons continue to perform simple 
avulsion polypectomy with good results (Larsen et al 1997). 
ESS involves restoring sinus drainage by careful removal 
of NP or other soft tissue obstructing the natural sinus ostia 
(Messerklinger et al 1987). This can be done by traditional 
snare polypectomy, cold steel instruments, or the increas-
ingly more common technique of micro-debridement, 
which involves a rotating blade in combination with suc-
tion and irrigation. There is some research available that 
radical endoscopic sinus procedures involving complete 
fronto-sphenoidectomies lead to greater perceived beneﬁ  ts 
(Jacobsen et al 2000). More extensive surgery can lead to 
increased risk of operative complications but to date no com-
parative study exists between radical and limited surgery.
There is little doubt that ESS offers better visualiza-
tion and scope for precision surgery. The micro-debrider 
(Figure 4) in particular enables accurate removal of NP whilst 
preserving normal anatomical structures such as the turbi-
nates. Serious complications of ESS are rare but the patient 
must be counseled preoperatively about the potential risks 
such as loss of vision, damage to the internal carotid artery, 
and cerebrospinal ﬂ  uid leakage after inadvertent trauma to 
the skull base (Stammberger et al 1999).
It is important postoperatively to regularly douche the 
nasal cavity with saline to prevent crusting and adhesions. 
Topical intranasal steroids are also a routine part of after-
surgery care to prevent recurrence. Rowe Jones and col-
leagues (2005) studied a group of 109 patients prospectively 
for 5 years postoperatively. Seventy two patients attended the 
5 year follow-up visit. All patients were entered in a random-
ized double blinded controlled study of ﬂ  uticasone propionate 
aqueous spray. Symptom scores were signiﬁ  cantly better in 
the treatment group at 5 years (Rowe Jones et al 2005).
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